Navigation Links
AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
Date:2/17/2011

ALISO VIEJO, Calif., Feb. 17, 2011 /PRNewswire/ -- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) today announced the promotion of Gregory J. Flesher to the position of Senior Vice President of Corporate Development and Chief Business Officer.  In this role, Mr. Flesher will oversee corporate strategy, business development, program management, and business operations.

"Greg has shown exceptional leadership over the past several years and has played a key role in the transformation of AVANIR into a commercial-stage organization," said Keith Katkin, President and Chief Executive Officer.  "His broad pharmaceutical background in business development, sales and marketing, and research and development provides a strong foundation which will help AVANIR grow into a successful CNS company.  I look forward to Greg's continued contributions to the executive management team."

Mr. Flesher has over 16 years of experience in the pharmaceutical industry.  He was previously Vice President of Business Development for AVANIR, with responsibility for business transactions, intellectual property, and NUEDEXTA™ lifecycle planning.  Prior to joining the Company, he held various positions of increasing responsibility at InterMune Inc., Amgen Inc., and Eli Lilly and Company.

Mr. Flesher graduated from Purdue University with a degree in Biology and has completed his doctorate coursework in Biochemistry and Molecular Biology at Indiana University School of Medicine.

About AVANIR Pharmaceuticals, Inc.

AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about AVANIR, please visit www.avanir.com.

AVANIR™ and NUEDEXTA™ are trademarks owned by AVANIR Pharmaceuticals, Inc.

©2011 AVANIR Pharmaceuticals, Inc. All Rights Reserved.


'/>"/>
SOURCE AVANIR Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
2. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
3. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
4. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
6. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
7. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
8. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
9. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
10. Cumberland Pharmaceuticals to Announce 2010 Financial Results on March 8, 2011
11. Valeant Pharmaceuticals to Present at RBC Capital Markets 2011 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... BUDAPEST , Ungarn, February 12, 2016 ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ... gab heute positive Ergebnisse seines klinischen Forschungsprogramms ... und Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen ... Indiso ltd , ein Medizintechnikunternehmen, das ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... DDi , a Makro company, makes it to ... in eClinical Solutions. DDi has built its solution competency with a unique blend ... DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by providing ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... over 250 members of South Florida’s philanthropic community at its 10th anniversary Fashion ...
(Date:2/12/2016)... ... 2016 , ... Coco Libre, the maker of coconut water beverages with a ... Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut ... invitation-only gifting suite, held this year at the W Hollywood Hotel, has become a ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman ... John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, ... VA Southern Nevada Healthcare System. This will be the first Fisher House in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young ... area, celebrates the beginning of the latest charity campaign in their community enrichment ... art. Donations to this worthy cause are currently being accepted at: http://artexpressioninc.org/ ...
Breaking Medicine News(10 mins):